Clinical evidence suggests that nebulized colistimethate sodium (CMS) has benefits for
treating lower respiratory tract infections caused by multidrug-resistant Gram-negative …

Colistin (polymyxin E) is a positively charged deca-peptide antibiotic that disrupts the
integrity of the outer membrane of the cell wall of gram-negative bacteria by binding to the …

The polymyxins, colistin (also known as polymyxin E) and polymyxin B, have a unique and
interesting history. Originally introduced in the 1950s for the treatment of infections owing to …

Pseudomonas aeruginosa is involved in a variety of difficult-to-treat infections frequently due
to biofilm formation. To identify useful antibiofilm strategies, this article evaluated efficacy of …

Background Safe and effective use of colistin requires robust pharmacokinetic (PK) and
pharmacodynamic (PD) data to guide dosing. Aim To evaluate the pharmacokinetics of …

In the present study, we employed untargeted metabolomics to investigate the synergistic
killing mechanism of polymyxin B in combination with an aminoglycoside, amikacin, against …

Objectives Colistin is an 'old'drug, which is being increasingly utilized due to limited
therapeutic options. However, resistance emergence during monotherapy is concerning …

Purpose This study aims to develop liposomal formulations containing synergistic antibiotics
of colistin and ciprofloxacin for the treatment of infections caused by multidrug-resistant …

Objectives In clinical practice, colistin is used as combination therapy to improve its
antibacterial activity, despite the consequent increase in toxicity. This prospective …

Introduction: Identifying the optimized dosing regimen and algorithm is critical in the
development of antibiotics. Suboptimal regimens and inappropriate choice of drug give rise …